Scientific expertise. Creative insight.
Daiichi Sankyo is dedicated to the innovative development and commercialization of pharmaceutical products that address diversified, unmet medical needs in mature and emerging markets. We draw upon the scientific expertise of our researchers, as well as the creativity and diverse thinking of our employees to create world-class products.
Our commitment to the discovery, development and delivery of innovative medicines dates back more than a century ago when Daiichi Sankyo scientists first discovered epinephrine (also known as adrenaline,). Our passion for innovation continued and led to the isolation of B vitamins, thedevelopment of the first statin (a class of medications used to treat high cholesterol) and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes. These discoveries have made a huge impact in the medical field and improved the lives of patients with chronic diseases.
Every day, our scientists focus on streamlining the journey from discovery to approval of new compounds with enormous therapeutic potential. Whether focusing on our portfolio of medicines to treat cardiovascular and metabolic diseases, or expanding our pipeline of oncology therapies, Daiichi Sankyo is committed to creating first-in-class and best-in-class therapies. Our comprehensive portfolio offers a wide range of treatments for patients in a number of disease categories including hypertension, heart disease, diabetes and hyperlipidemia/atherosclerosis.
Click here to visit our corporate site for more information.